Immunological Density Shapes Recovery Trajectories in Long COVID

TL;DR

Post-acute sequelae of SARS-CoV-2 infection (Long COVID) often persist, and this study addresses whether spontaneous recovery occurs with time or requires immunological perturbation. Using a large longitudinal dataset of $97{,}564$ PASC assessments from $13{,}511$ participants with linked vaccination histories, the authors classify trajectories into three phenotypes and analyze associations with time since vaccination and cumulative doses. They find that baseline severity is largely deterministic and that recovery is strongly tied to repeated immunization, with Responders showing about $20.7\%$ symptom reduction by Dose 5, rather than spontaneous improvement over time. These results underscore immunological density as a driver of recovery and suggest vaccine-based strategies could induce remission in dose-responsive individuals.

Abstract

Post-acute sequelae of SARS-CoV-2 infection (Long COVID) frequently persists for months, yet drivers of clinical remission remain incompletely defined. Here we analyzed 97,564 longitudinal PASC assessments from 13,511 participants with linked vaccination histories to disentangle passive temporal progression from vaccine-associated change. Using a clinically validated threshold (PASC $\geq 12$), trajectories separated into three phenotypes: Protected (persistently sub-threshold), Refractory (persistently symptomatic), and Responders (transitioning from symptomatic to recovered). Across the full cohort, symptom severity increased modestly with elapsed time ($r=0.0521$, $P=1.26\times10^{-59}$), whereas cumulative vaccination showed an inverse association with severity ($r=-0.0434$, $P=5.95\times10^{-42}$). In summary, baseline Long COVID severity appears clinically deterministic. In the absence of intervention, symptoms typically persist without spontaneous resolution. Recovery is primarily associated with repeated immunization.

Figures (10)

• Figure 1: Protected, Responder and Refractory subcohort from RECOVER Adult.
• Figure 2: Distribution of PASC severity across patient cohorts.A, Distribution of peak PASC severity and individual score variance. B, Distribution of initial PASC severity and individual score variance.
• Figure 3: Baseline severity and longitudinal course distinguish Protected, Responder, and Refractory PASC phenotypes.
• Figure 4: Dose distribution at initial PASC.
• Figure 5: PASC severity shows weak but significant correlations with time and prior vaccination across phenotypes.